Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Spur Therapeutics logo — Toward the next generation of gene therapy.

Spur Therapeutics

Toward the next generation of gene therapy.

Founded 2015 United Kingdom Stevenage, United Kingdom 122 employees Post-IPO Equity Total: $260.50M Biopharma, Biotechnology +3

General Information

Company Name Spur Therapeutics
Founded Year 2015
Location United Kingdom Stevenage, United Kingdom
Employees 122
Industries Biopharma, Biotechnology, Health Care +2
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Spur Therapeutics. To contact Spur Therapeutics, visit spurtherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Spur Therapeutics compare?

A PDF of Spur Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Spur Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Spur Therapeutics

Freeline is a biopharmaceutical company focused on developing liver-directed gene therapies for inherited systemic diseases. With clinical programs for Hemophilia B and Fabry disease, and preclinical programs in Gaucher disease and haemophilia A, the company aims to revolutionize treatment options for individuals suffering from debilitating inherited diseases. Founded in 2015, Freeline is based in the United Kingdom, with additional locations in the United States and Germany. The company recently received a notable $26.10M post-IPO equity investment on 10 March 2022, with Syncona Investment Management as the investors. This significant funding reflects investor confidence in Freeline's innovative approach to gene therapy, positioning the company for further growth and impact in the biopharma, biotechnology, and life sciences industries.

Business keywords: gene therapy, liver-directed, inherited diseases, clinical trials, AAV-based therapy, Hemophilia B, Fabry disease, Gaucher disease, haemophilia A, innovation, global locations, systemic diseases, United Kingdom, United States

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $26.10M 1
Syncona Investment Management
Syncona Investment Management
10 Mar 2022
Series C $80.00M 6
Novo Holdings Wellington Management Acorn Bioventures
Novo Holdings, Wellington Management +4
30 Jun 2020
Series C $40.00M 1
Syncona Investment Management
Syncona Investment Management
19 Dec 2019
Grant Undisclosed 1
Innovate UK
Innovate UK
24 May 2019
Series B £88.40M 2
Syncona Investment Management UCL Tech Fund
Syncona Investment Management, UCL Tech Fund
20 Jun 2018
Series A £1.00M 1
UCL Tech Fund
UCL Tech Fund
22 Jun 2016
Series A £25.00M 1
Syncona Investment Management
Syncona Investment Management
11 Dec 2015

Spur Therapeutics Alternatives & Competitors

View All Alternatives
Spur Therapeutics vs
Exegenesis Bio
Exegenesis Bio United States

We are reimagining ways to develop & manufacture gene therapies. Our mission is to improve efficacy...

Series B
17 employees
Biotechnology, Health Care
Compare Spur Therapeutics vs Exegenesis Bio
Spur Therapeutics vs
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. United States

This company is now integrated into the Roche Group, united in our commitment to do now what patient...

Acquired
304 employees
Biotechnology, Health and Wellness
Compare Spur Therapeutics vs Spark Therapeutics, Inc.
Spur Therapeutics vs
Vivet Therapeutics
Vivet Therapeutics France

Vivet Therapeutics develops gene therapy treatments for inherited liver disorders using liver tropic...

Grant
16 employees
Biopharma, Biotechnology
Also compare with: Spur Therapeutics vs Taysha Gene Therapies Taysha Gene Therapies View all alternatives

FAQ About Spur Therapeutics

Toward the next generation of gene therapy.
Spur Therapeutics was founded in 2015.
Spur Therapeutics is headquartered in Stevenage, United Kingdom.
Spur Therapeutics operates in Biopharma, Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on gene therapy, liver-directed, inherited diseases and clinical trials.
Spur Therapeutics has approximately 122 employees.
Spur Therapeutics has completed 7 funding rounds, raising a total of $260.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Spur Therapeutics include Exegenesis Bio, Spark Therapeutics, Inc., Vivet Therapeutics, AAVantgarde, AVROBIO. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Spur Therapeutics and Exegenesis Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Spur Therapeutics, https://bouncewatch.com/company/freeline, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes